Fig. 2
From: Does postoperative chemotherapy improve overall survival of patients with ypT1-2N0 cancer?
Overall survival (OS) based on whether patients received postoperative chemotherapy. A OS for clinical T2 patients. B OS for clinical T3–4 patients. C OS for patients without clinical lymph node metastasis. D OS for patients with clinical lymph node metastasis. E OS for patients with well/moderate differentiation. F OS for patients with poor differentiation. G OS for patients with lymphovascular invasion. H OS for patients without lymphovascular invasion